(Q35032959)

5 August 2017

1 reference

title

Immunity and schizophrenia: autoimmunity, cytokines, and immune responses (English)

1 reference

5 August 2017

1 reference

Fiona Gaughran

1

0 references

publication date

1 January 2002

1 reference

International Review of Neurobiology

5 August 2017

published in

1 reference

5 August 2017

volume

52

1 reference

5 August 2017

page(s)

275-302

1 reference

Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

T-cell subsets in acute psychotic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Interleukin-2 modulates evoked release of [3H]dopamine in rat cultured mesencephalic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Preschizophrenics: adding to the evidence, sharpening the focus

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Plasma interleukin-1 beta and sleep architecture in schizophrenia and other nonaffective psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Production of interferon-gamma in families with multiple occurrence of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Decreased expression of the embryonic form of the neural cell adhesion molecule in schizophrenic brains

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Serum Interferon in First Psychotic Attack

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Cholesterol and mental disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Second-trimester markers of fetal size in schizophrenia: a study of monozygotic twins

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Neuroleptic-associated autoantibodies. A prevalence study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Possible Biological Advantages among Schizophrenics' Relatives

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Biological significance of soluble IL-2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Increased levels of CD8+ and CD4+ 45RA+ lymphocytes in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Cytokine profiles in drug-naive schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Left-handed first-episode, neuroleptic-naive schizophrenic patients have a higher prevalence of autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Obstetric complications and autoantibodies in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Elevated IgG anti-histone antibodies in a subgroup of medicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Serum immunoglobulin levels in Chinese male schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Quantitative determination of immunoglobulins in CSF and plasma of chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Deficient natural killer cell (NK) activity and macrophage functioning in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Serum immunoglobulin concentrations in patients admitted to an acute psychiatric in-patient service

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Relapsed Schizophrenics: Earlier Discharge from the Hospital After Cereal-Free, Milk-Free Diet

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Schizophrenia and rheumatoid arthritis: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Effect of acute metabolic stress on pituitary-adrenal axis activation in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

The "antibrain" factors in psychiatric patients' sera. I. Further studies with a hemagglutination technique.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Juvenile onset diabetes and schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Anticardiolipin antibodies are elevated in drug-free, multiply affected families with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Natural autoantibodies in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

CD5 positive B lymphocytes in schizophrenia: No alteration in numbers or percentage as compared with control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Clinical and laboratory evidence of autoimmunity in acute schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Negative symptoms of schizophrenia and the dexamethasone suppression test

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Increased soluble interleukin 2 receptor levels in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Soluble interleukin 2 receptor levels in acute and stable schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Soluble interleukin 2 receptor levels in families of people with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Exposure to infection and brain development: cytokines in the pathogenesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Family history of autoimmune diseases in psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Motoric laterality imbalance in schizophrenia. A possible concomitant of left hemisphere dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Modulation of hippocampal acetylcholine release: a potent central action of interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Schizophrenia as an immunologic disorder. 3. Effects of antimonkey and antihuman brain antibody on brain function

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Antiseptal brain antibody in IgG of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Increased prevalence of antibrain antibodies in the sera from schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Interferon responses in schizophrenia and major depressive disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Child development risk factors for adult schizophrenia in the British 1946 birth cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Blunted acth response to hypoglycemic stress in depressed patients but not in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Antibody to discrete areas of the brain in normal individuals and patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Decreased interleukin-2 production in Korean schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Can autoimmune mechanisms account for the genetic predisposition to schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Atypical lymphocytes in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

A role for interleukin-2 in the regulation of striatal dopaminergic function

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Immunoglobulins, autoantibodies and other serum protein fractions in psychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Side effect profile of azathioprine in the treatment of chronic schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Catching up on schizophrenia: natural history and neurobiology

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Elevated central levels of interleukin-2 in drug-free schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Adenosine: a mediator of interleukin-1beta-induced hippocampal synaptic inhibition.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Psychoneuroendocrinology of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Lymphocyte subsets in schizophrenic disorders. Relationship with clinical, neuromorphological and treatment variables

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Increased numbers of CD5+ B lymphocytes in schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Natural killer cell activity in schizophrenia and schizoaffective disorder: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Tumor necrosis factor alpha, interleukin 1 and related cytokines in brain development: normal and pathological

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Decreased production of interferon alpha and interferon gamma in leucocyte cultures of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Multihormonal responses to apomorphine in mental illness

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Serum antibodies to nicotinic acetylcholine receptors in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Immunoglobulin and albumin content of cerebrospinal fluid in schizophrenic patients: relationship to negative symptomatology

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Cellular immunity in schizophrenic patients before and during neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

The role of immune function in schizophrenia: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Effect of chronic treatment with recombinant interleukin-2 on the central nervous system of adult and old mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Abnormal distributions of T-lymphocyte subsets in the cerebrospinal fluid of patients with acute schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Brain morphology in first-episode schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Familial, obstetric, and other clinical correlates of minor physical anomalies in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Risk of schizophrenia in adults born after obstetric complications and their association with early onset of illness: a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Hypothesis: low serum cholesterol, suicide, and interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Effects of clozapine on plasma cytokine and soluble cytokine receptor levels

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Serum interferon in patients with psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Increased serum soluble interleukin-2 receptors in schizophrenic monozygotic twins

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Specific IgA antibody increases in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Immunoglobulin studies in patients with psychiatric diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Cytokine production in unmedicated and treated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Hepatitis B vaccination in psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

PHENOTHIAZINE EFFECT ON HUMAN ANTIBODY SYNTHESIS

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Increased anti-Sm antibodies in schizophrenic patients and their families.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Is schizophrenia linked to alteration in cellular immunity?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Reduced total complement haemolytic activity in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Ganglioside antibodies in schizophrenia and major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Oligoclonal bands in acute schizophrenia: a negative search

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 1944-1945.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Serum interleukin-18 levels are elevated in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Cytokine serum levels, autologous mixed lymphocyte reaction and surface marker analysis in never medicated and chronically medicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Immunity and schizophrenia; a survey of the ability of schizophrenic patients to develop an active immunity following the injection of pertussis vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Schizophrenia: developmental neuroscience and pathobiology

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Effects of neuroleptic treatment on cortisol and 3-methoxy-4-hydroxyphenylethyl glycol levels in blood

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Acute phase proteins in male Chinese schizophrenic patients in Singapore

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Autoimmune diseases in the pedigrees of schizophrenic and control subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Schizophrenia and HLA: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6.

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Immunologic and Coagulation Disorders in Chlorpromazine-Treated Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Schizophrenia and physical disease

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

Interleukin-2 modulates calcium currents in dissociated hippocampal CA1 neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0074-7742%2802%2952013-4

7 January 2021

10.1016/S0074-7742(02)52013-4

Identifiers

DOI

1 reference

5 August 2017

1 reference